Pantoprazole Reduces GI Bleeding Risk in Critically Ill Children With Coagulopathy, Suggests Study
A recent study published in Indian Pediatric in June 2025 reveals that while routine stress ulcer prophylaxis isn't universally beneficial for all critically ill children, intravenous pantoprazole impressively halves the risk of gastrointestinal bleeding for those specifically suffering from coagulopathy.
To broadly address the essential clinical need for effective preventative strategies in pediatric intensive care, researchers Ananya Kavilapurapu, A V Lalitha, and Santu Ghosh aimed to comprehensively evaluate the efficacy of intravenous pantoprazole as a reliable stress ulcer prophylaxis to prevent GI bleeding in sick children.
Therefore, the randomized trial of 301 critically ill children evaluated whether intravenous pantoprazole prevents gastrointestinal bleeding better than a placebo. The researchers also assessed secondary outcomes, including bleeding onset time, pneumonia risk, hospital stay duration, organ dysfunction, and overall mortality.
Key Clinical Findings of the Study Includes:
• Overall Incidence: Research revealed no statistically significant difference in the general incidence of GI bleeding between the pantoprazole treatment cohort (21 out of 151) and the placebo cohort (19 out of 150).
• Clinically Significant Bleeding: Investigations demonstrated comparable results for clinically significant GI bleeding, affecting approximately 1.3% of children in the targeted treatment group versus 0.6% in the placebo group.
• Overt Bleeding Rates: Researchers observed remarkably similar rates of overt GI bleeding across both study arms, reported at precisely 12.6% for intravenous pantoprazole and 12% for the normal saline placebo.
• Coagulopathy Subgroup Benefit: Analysis highlighted a significantly reduced incidence of GI bleeding in children with coagulopathy receiving pantoprazole (n=29) compared to the placebo group (n=25), documenting a clear protective relative risk of 0.52.
The results suggest that while routine pantoprazole prophylaxis fails to broadly diminish the overall incidence of GI bleeding in critically ill children (21/151 versus 19/150), it provides a notable and statistically significant protective advantage specifically for those pediatric patients presenting with concurrent coagulopathy.
Thus, the study concludes that practicing clinicians might consider prioritizing proton pump inhibitor prophylaxis primarily for critically ill pediatric patients who exhibit concurrent signs of coagulopathy, rather than applying it as a universal preventative measure across all intensive care admissions.
Reference
Kavilapurapu A, Lalitha AV, Ghosh S. Role of Proton Pump Inhibitor as Stress Ulcer Prophylaxis in Sick Children: A Randomized Controlled Trial. Indian Pediatr. 2025 Jun;62(6):407-413.
